The frequency question becomes "zero doses" once pregnancy is planned or confirmed
Clinical trials show that Tirzepatide often outperforms Semaglutide in terms of weight loss, with some patients losing up to 20% of their body weight
In January 2025, Novo Nordisk stated that the United States Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease progression, kidney failure (end-stage renal disease), and cardiovascular disease-related death in individuals with type 2 diabetes and chronic kidney disease (CKD)
In conclusion, GLP-1RAs may effectively improve the clinical symptoms of COPD patients, alleviate airflow limitation, airway damage, fibrosis, and remodeling, shorten the hospital stay, reduce the economic burden of patients, and reduce the occurrence of COPD-related complications, improve the long-term prognosis of patients, thus playing a therapeutic and preventive role for COPD patients, and may provide a new target for the prevention and treatment of COPD